SCHEMBL4808573

SCHEMBL4808573

Cn1c(Cc2ccc(Cl)c(Oc3cc(Cl)cc(C#N)c3)c2F)n[nH]c1=O

nearest known ligand 0.84

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.84
CYP2C9 P11712 3/20 0.59
CYP2C19 P33261 2/20 0.59
KCNH2 Q12809 6/20 0.59
MTNR1B P49286 1/20 0.36
CYP2D6 P10635 1/20 0.35
SLC22A12 Q96S37 1/20 0.32
HTR2A P28223 1/20 0.32
CRHR1 P34998 1/20 0.32
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
PKM P14618 1/20 0.31
VEGFA P15692 2/20 0.31
EPAS1 Q99814 2/20 0.31
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
NPBWR1 P48145 1/20 0.30
MCHR1 Q99705 1/20 0.30
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4800446 0.95 CYP3A4 (0.76) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL4807889 0.93 CYP3A4 (0.84) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL14262139 0.92 CYP3A4 (1.00) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL4801545 0.91 CYP3A4 (0.82) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL5322461 0.90 CYP3A4 (0.80) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL4810352 0.89 CYP3A4 (0.68) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL4807023 0.89 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL4807779 0.89 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19KCNH2MTNR1B
SCHEMBL4581717 0.86 CYP3A4 (0.64) CYP3A4CYP2C9CYP2C19KCNH2CYP2D6
SCHEMBL11904765 0.86 CYP3A4 (0.63) CYP3A4CYP2C9CYP2C19KCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348345-B2 Nonnucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-03-25 US disclosed
US-7348345-B2 Nonnucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-03-25 US disclosed
US-7348345-B2 Nonnucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-03-25 US disclosed
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors DUNN JAMES P 2007-08-02 US disclosed
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors DUNN JAMES P 2007-08-02 US disclosed
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors DUNN JAMES P 2007-08-02 US disclosed
US-7208509-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-04-24 US disclosed
US-7208509-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-04-24 US disclosed
US-7208509-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179157-A1 Nonnucleoside reverse transcriptase inhibitors RRM2, RRM2B, SAMHD1 CYP3A4 438/4885CYP2C9 1755/4885CYP2C19 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.